Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steven I Park

Showing results (21-30 of 50) with videos related to

Pageof 5
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|January 15, 2022
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b StudyM Lia Palomba, Brian G Till, Steven I Park, et al.
Bioconjugate Chemistry|July 6, 2010
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutantsD Scott Wilbur, Steven I Park, Ming-Kuan Chyan, et al.
American Journal of Hematology|June 17, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell LymphomaStephen D Smith, Suchitra Sundaram, Sharmila Giri, et al.
British Journal of Haematology|July 23, 2016
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphomaSteven I Park, Natalie S Grover, Oludamilola Olajide, et al.
Investigational New Drugs|August 23, 2018
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphomaTycel Phillips, Paul M Barr, Steven I Park, et al.
Leukemia & Lymphoma|June 19, 2018
Deferred treatment is a safe and viable option for selected patients with mantle cell lymphomaOscar Calzada, Jeffrey M Switchenko, Joseph J Maly, et al.
Targeted Oncology|August 21, 2019
Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing LymphomaSteven I Park, Carolina P Lin, Natalie Ren, et al.
Blood|June 12, 2009
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primatesDamian J Green, John M Pagel, Eneida R Nemecek, et al.
Cancer|July 21, 2021
Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphomaBei Hu, Danielle Boselli, Lisa M Pye, et al.
The Lancet. Haematology|March 19, 2017
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trialsSonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, et al.
Pageof 5

Showing results (21-30 of 50) with videos related to

Sort By:
Pageof 5
Clinical Lymphoma, Myeloma & Leukemia|January 15, 2022
Combination of Atezolizumab and Obinutuzumab in Patients with Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma: Results from a Phase 1b StudyM Lia Palomba, Brian G Till, Steven I Park, et al.
Bioconjugate Chemistry|July 6, 2010
Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutantsD Scott Wilbur, Steven I Park, Ming-Kuan Chyan, et al.
American Journal of Hematology|June 17, 2026
Outcomes From the Multicenter ACCRU-LY-1804/CARiBOU TRIAL (Cytarabine, Acalabrutinib and Rituximab Integrated With Bortezomib-Based Outpatient Therapy) in 1st Line Mantle Cell LymphomaStephen D Smith, Suchitra Sundaram, Sharmila Giri, et al.
British Journal of Haematology|July 23, 2016
A phase II trial of bendamustine in combination with rituximab in older patients with previously untreated diffuse large B-cell lymphomaSteven I Park, Natalie S Grover, Oludamilola Olajide, et al.
Investigational New Drugs|August 23, 2018
A phase 1 trial of SGN-CD70A in patients with CD70-positive diffuse large B cell lymphoma and mantle cell lymphomaTycel Phillips, Paul M Barr, Steven I Park, et al.
Leukemia & Lymphoma|June 19, 2018
Deferred treatment is a safe and viable option for selected patients with mantle cell lymphomaOscar Calzada, Jeffrey M Switchenko, Joseph J Maly, et al.
Targeted Oncology|August 21, 2019
Inhibition of Aurora A Kinase in Combination with Chemotherapy Induces Synthetic Lethality and Overcomes Chemoresistance in Myc-Overexpressing LymphomaSteven I Park, Carolina P Lin, Natalie Ren, et al.
Blood|June 12, 2009
Pretargeting CD45 enhances the selective delivery of radiation to hematolymphoid tissues in nonhuman primatesDamian J Green, John M Pagel, Eneida R Nemecek, et al.
Cancer|July 21, 2021
Equal access to care and nurse navigation leads to equitable outcomes for minorities with aggressive large B-cell lymphomaBei Hu, Danielle Boselli, Lisa M Pye, et al.
The Lancet. Haematology|March 19, 2017
Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trialsSonali M Smith, Brandelyn N Pitcher, Sin-Ho Jung, et al.
Pageof 5